Actinogen Medical Launches Alzheimer ’s Trial
Actinogen Medical Limited (AU:ACW) has released an update. Actinogen Medical has announced the initiation of their phase 2b XanaMIA clinical trial,...#acw #actinogenmedical (Source: Reuters: Health)
Source: Reuters: Health - April 15, 2024 Category: Consumer Health News Source Type: news
What is the Dose-Response for Maternal Vitamin D Supplementation in Lactating Mothers?
Discussion
Vitamin D is an important vitamin for bone formation and mineral homeostasis. Hypocalcemia, hypophosphatemia, osteomalacia, rickets and tetany can all result because of Vitamin D deficiency. Deficiency is caused by inadequate dietary intakes of Vitamin D, inadequate exposure to sunlight or patients with fat malabsorption or renal disease. Even in high sun exposure areas of the world, Vitamin D deficiency can occur because of inadequate exposure due to clothing or cultural practices. Sunscreen blocks sunlight and an SPF (sun protection factor) of 8 blocks 95% of the sun, so there needs to be a careful balance bet...
Source: PediatricEducation.org - April 15, 2024 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
FDA ’s ODAC Votes 12 to 0 That MRD Is a Viable End Point in Myeloma Trials
In a 12 to 0 vote, the FDA’s Oncologic Drugs Advisory Committee (ODAC) decided that evidence supported that minimal residual disease (MRD) could be used as an accelerated approval end point in clinical trials of multiple myeloma. “I think the sets a precedence of actually moving the field forward,…#fda #odac #mrd #ranjanahadvani #saulrosenberg #nicolegormley #approval #bindukanapuru #kanapuru #colalandgren (Source: Reuters: Health)
Source: Reuters: Health - April 13, 2024 Category: Consumer Health News Source Type: news
Free educational videos demystify systematic reviews
Having a good understanding of what trusted healthcare evidence is enables us to make more informed healthcare decisions. These four brief videos tailored for patients, caregivers, students, and healthcare professionals, provide a deeper understanding of systematic reviews.Four brief animations have been co-produced by theCochrane Crowd team,Evidence Synthesis Ireland, and the public. They are designed for patients, the public, healthcare professionals, students and more, who want to learn about systematic reviews and the main steps involved in producing a review.
They are free to use for teaching public and patient inv...
Source: Cochrane News and Events - April 12, 2024 Category: Information Technology Authors: Muriah Umoquit Source Type: news
Unapproved weight loss jab nicknamed 'triple G' and made in Chinese labs is being illegally sold online for as little as £2 a pop
Online hawkers are chasing in on the hype surrounding new weight loss jabs and are now selling Brits a drug that is clinical trials and years away from being approved for use. (Source: the Mail online | Health)
Source: the Mail online | Health - April 12, 2024 Category: Consumer Health News Source Type: news
Invex Therapeutics Advances Exenatide Development
Invex Therapeutics Ltd. (AU:IXC) has released an update. Invex Therapeutics Ltd has concluded its Phase III IIH EVOLVE clinical trial and is now fo...#invextherapeuticsltd #ixc #phaseiiiiihevolve (Source: Reuters: Health)
Source: Reuters: Health - April 12, 2024 Category: Consumer Health News Source Type: news
The Push for a Better Dengue Vaccine Grows More Urgent
A public research institute in Brazil has proved a new shot protects against the disease, but can ’t make it fast enough to stop the huge outbreak sweeping Latin America. (Source: NYT Health)
Source: NYT Health - April 11, 2024 Category: Consumer Health News Authors: Stephanie Nolen Tags: Dengue Fever Vaccination and Immunization Disease Rates Clinical Trials Deaths (Fatalities) Medicine and Health Global Warming Drugs (Pharmaceuticals) Infections Merck & Company Inc National Institutes of Health Brazil your-fee Source Type: news
Long Covid trials aim to clear lingering virus —and help patients in need
One Monday morning last September, Shelley Hayden pulled into a parking spot in an underground garage at the University of California San Francisco (UCSF). She switched off the ignition, pushed the red record button on her cellphone, and gazed into the camera. “The time has come,” said Hayden, long dark-blond hair framing her blue eyes. “Here we are, I’m actually getting to do something.”
More than 3 years earlier, in the summer of 2020, Hayden had come down with COVID-19 while visiting family in Colorado. Since then she’s been plagued by the disease’s cruel sequel, Long Covid, whose symptoms include ov...
Source: ScienceNOW - April 11, 2024 Category: Science Source Type: news
More Adults Are Participating in Cancer Clinical Trials More Adults Are Participating in Cancer Clinical Trials
New estimates suggest that more adults with cancer are participating in cancer trial research, especially at National Cancer Institute –designated centers, but overall enrollment rates remain low.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 11, 2024 Category: Cancer & Oncology Tags: Hematology-Oncology Clinical Summary Source Type: news
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
The Elecsys ® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in identifying amyloid pathology, a key feature of Alzheimer ’s diseaseRoche and Lilly believe the test could play an important role in improving access to early and accurate Alzheimer ’s diagnosisBasel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed ...
Source: Roche Investor Update - April 11, 2024 Category: Pharmaceuticals Source Type: news
Roche granted FDA Breakthrough Device Designation for blood test to support earlier Alzheimer's disease diagnosis
The Elecsys ® pTau217 plasma biomarker test is being developed as part of an ongoing partnership between Roche and Eli Lilly and CompanyOnce approved, the test will aid healthcare providers in identifying amyloid pathology, a key feature of Alzheimer ’s diseaseRoche and Lilly believe the test could play an important role in improving access to early and accurate Alzheimer ’s diagnosisBasel, 11 April 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that its Elecsys pTau217 assay received Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA). This blood test, which is being developed ...
Source: Roche Media News - April 11, 2024 Category: Pharmaceuticals Source Type: news
Effects of respiratory exercises in sleep bruxism and associated obstructive sleep apnea: a double-blind, placebo-controlled randomized clinical trial
Conclusion: Respiratory physical therapy for OSA improved awaking levels in 80 and 67% of the number of masseter muscle contractions, when compared to placebo. (Source: Dental Technology Blog)
Source: Dental Technology Blog - April 10, 2024 Category: Dentistry Source Type: news
Rett Syndrome Research Trust Launches the MECP2 Editing Consortium With Goal to Advance Programs to Clinical Trials
The Rett Syndrome Research Trust (RSRT) has taken a significant stride in the pursuit of innovative genetic medicines for Rett syndrome by establishing the MECP2 Editing Consortium. Mutations in MECP2 cause Rett syndrome, a debilitating neurological disorder that causes a lifetime of... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 10, 2024 Category: Pharmaceuticals Source Type: news
Navigate Placebo Response: Insights and Mitigation Strategies for Clinical Excellence, Upcoming Webinar Hosted by Xtalks
In this free webinar, discover the key ideas to mastering placebo responses in clinical trials in 2024 and beyond. Attendees will learn about the latest biological insights and pragmatic mitigation strategies for trial success. The featured speakers will discuss how to enhance treatment... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - April 10, 2024 Category: Pharmaceuticals Tags: FVT TDS Source Type: news
Cytokinetics Announces Three Late Breaking Clinical Trial Presentations Relating to SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 …
Primary Results from SEQUOIA-HCM to Elaborate on Positive Topline Results in Patients with Obstructive Hypertrophic Cardiomyopathy Two Additional Analyses from SEQUOIA-HCM Assess Effect of Aficamten on Exercise Capacity and Dosing and Safety SOUTH SAN FRANCISCO, Calif., April 10, 2024 (GLOBE…#primaryresults #incorporatedcytk #sequoiahcm #efficacy #phase3 #hcm #heartfailure #lisbon #portugal #martinmaron (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
